Impact of Sleep Disturbances Treatment in Patients With Fibromyalgia: A Scoping Review
Journal of Sleep Research · 2026-08 · 35 (4)
DOI: 10.1111/jsr.70296 ↗Kurz gefasst
Scoping Review in der Zeitschrift Journal of Sleep Research, online erschienen am 16.02.2026. Verfasst von Milena Araújo Dos Santos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Morgana Potrich College (FAMP), Mineiros, Goiás, Brazil. Hauptthemen laut MEDLINE: Fibromyalgia, Sleep Wake Disorders. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Fibromyalgia (FM) is a chronic clinical syndrome characterised by widespread musculoskeletal pain, fatigue and sleep disturbances, with non‐restorative sleep being a central symptom that severely exacerbates the condition. Although management is multidisciplinary, the role of interventions specifically directed at sleep as a primary pathway to improve core FM symptoms requires systematisation. The objective of this scoping review was to map the therapeutic approaches, both pharmacological and non‐pharmacological, that address sleep disturbances in FM patients, identifying their characteristics, outcomes and evidence gaps. The review was conducted in accordance with the JBI and PRISMA‐ScR guidelines. The search, restricted to articles published between 2020 and 2024, was performed in the PubMed, SciELO and ScienceDirect databases, utilising descriptors such as ‘fibromyalgia’, ‘sleep disorders’ and ‘therapeutics’. Nine studies met the inclusion criteria (six non‐pharmacological, three pharmacological). Non‐pharmacological interventions (including diet, manual therapies, and biofeedback) showed mixed results, often without a significant impact on primary sleep outcomes. Repetitive Transcranial Magnetic Stimulation (rTMS) and the drug Suvorexant stood out as the most promising strategies, demonstrating statistically significant improvement in both sleep quality (objective and subjective measures) and core FM symptoms. The field of study is characterised by high heterogeneity in interventions and outcomes, underscoring the need for high‐quality Randomised Controlled Trials that utilise objective sleep measures as primary outcomes to provide robust evidence. The mapping provided by this review guides future research in optimising sleep treatment, a critical factor in managing FM and improving patients' quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Morgana Potrich College (FAMP), Mineiros, Goiás, Brazil.
- Federal University of Goiás (UFG), Mineiros, Goiás, Brazil.
- Brazilian Association of Otolaryngology (ABORL), Mineiros, Goiás, Brazil.
- Federal University of Rio Grande do Norte (UFRN), Mineiros, Goiás, Brazil.
- Hospital Sírio-Libanês, São Paulo, São Paulo, Brazil.
- Health Services Management and Health Care Networks by PROADI-SUS (HSL), São Paulo, São Paulo, Brazil.
ORCID-Profile: Milena Araújo Dos Santos, Milena Camargo da Luz, Severino Correia do Prado Neto, Antonio Felipe Lopes Cavalcante, Lara Arcipreti Boel Souza
Zitieren
APA
Dos Santos, M. A., da Luz, M. C., do Prado Neto, S. C., Amanda de Almeida, S., Cavalcante, A. F. L., & Souza, L. A. B. (2026). Impact of Sleep Disturbances Treatment in Patients With Fibromyalgia: A Scoping Review. Journal of Sleep Research, 35(4). https://doi.org/10.1111/jsr.70296
Vancouver
Dos Santos MA, da Luz MC, do Prado Neto SC, Amanda de Almeida S, Cavalcante AFL, Souza LAB. Impact of Sleep Disturbances Treatment in Patients With Fibromyalgia: A Scoping Review. Journal of Sleep Research. 2026;35(4). doi:10.1111/jsr.70296
BibTeX
@article{DosSantos2026,
author = {Dos Santos, Milena Araújo and da Luz, Milena Camargo and do Prado Neto, Severino Correia and Amanda de Almeida, Souza and Cavalcante, Antonio Felipe Lopes and Souza, Lara Arcipreti Boel},
title = {Impact of Sleep Disturbances Treatment in Patients With Fibromyalgia: A Scoping Review},
journal = {Journal of Sleep Research},
year = {2026},
volume = {35},
number = {4},
doi = {10.1111/jsr.70296}
}
EUVIMED